Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Nov;65(7):e198-e202.
doi: 10.1111/ajd.14339. Epub 2024 Jun 19.

Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

Miguel Mansilla-Polo  1   2 , Martí Pons-Benavent  3 , Pablo Fernández-Crehuet  4 , Eva Vilarrasa  5 , Cristina Albanell-Fernández  6 , Enrico Morales-Tedone  6 , Francisca Rausell-Félix  6 , Rebeca Alcalá-García  7 , María Matellanes-Palacios  7 , Gemma Martín-Ezquerra  8 , Fernando Alfageme  9 , Cristina Ciudad-Blanco  10 , María Teresa López-Villaescusa  11 , Patricia Garbayo-Salmons  12 , Antonio Martorell  13 , Begoña Escutia-Muñoz  1   2 , Fernando Navarro-Blanco  1   2 , Daniel Martín-Torregrosa  1   2 , Carlos Cuenca-Barrales  14 , Alejandro Molina-Leyva  14 , Rafael Botella-Estrada  1   2   15
Affiliations
Observational Study

Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

Miguel Mansilla-Polo et al. Australas J Dermatol. 2024 Nov.

Abstract

In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.

Keywords: bimekizumab; biologic therapy; effectiveness; hidradenitis suppurativa; safety.

PubMed Disclaimer

References

REFERENCES

    1. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–1058.
    1. Sayed C, Shi V, Hsiao J, Kokolakis G, Kirby B, Piguet V, et al. Bimekizumab efficacy by prior biologic treatment in patients with moderate to severe hidradenitis suppurativa: 48‐week pooled data from the randomized, double‐blind, placebo‐controlled, multicenter BE HEARD I and II phase 3 trials. SKIN J Cutan Med. 2024;8(1):s349.
    1. Orenstein LA, Shi V, Lev‐Tov H, Prens E, Podda M, Fujita H, et al. Bimekizumab impact on pain in moderate to severe hidradenitis suppurativa: week 16 results from BE HEARD I & II. SKIN J Cutan Med. 2024;8(1):s350.
    1. Zouboulis CCG, Forman S, Weisman J, Szepietowski JC, Prens EP, Fujita H, et al. Bimekizumab efficacy and safety in patients with moderate to severe hidradenitis suppurativa: Analysis of pooled data from BE HEARD I & II phase 3, randomised, double‐blind, placebo‐controlled, multicentrestudies. EADV Congress 2023.
    1. Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double‐blind placebo‐controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279–1288.

Publication types

LinkOut - more resources